FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379344520> ?p ?o ?g. }

• W4379344520 endingPage "8013" @default.
• W4379344520 startingPage "8013" @default.
• W4379344520 abstract "8013 Background: Ide-cel is an FDA-approved treatment for RRMM patients (pts). However, there is limited data on how BT for disease control during its manufacturing process affects clinical outcomes. Methods: Eleven US academic centers contributed data to this analysis without involvement from the manufacturer. By 5/1/2022, 235 pts had undergone leukapheresis, with 214 infused with a median follow up of 9 months (mos). BT was given between leukapheresis and CAR-T infusion. Results: In this analysis, 79% of pts (n = 170) received BT, which included alkylator-based in 35.5%, steroid and/or IMiD/Ab combos (IMiD combos) in 14%, PI combinations (PI combos) in 12%, and selinexor in 10%. BT recipients had higher ECOG PS 2-4, R-ISS 2-3, ferritin, and CRP before lymphodepleting (LD) chemo, however, no difference among BT subgroups. No difference in prior lines of therapy or penta-refractory between BT and No BT (NBT) groups or BT subgroups. Median cycle of the BT was 1 (1-7), with overall response rate (ORR) of 12%, with no difference among BT subgroups. Incidence and severity of CRS and ICANs were comparable in BT and NBT. However, pts who received BT had a longer median hospital stay compared to NBT, particularly in the alkylator/selinexor subgroups. There were no significant difference in cytopenias at day 90 post CAR-T between the BT and NBT or BT subgroups. For the 73% (n = 157) evaluable for day 90 response, there was no difference in the complete or ORR between the BT and NBT groups (41% vs. 52%; p = .2 and 84% vs. 87.5%, p = .8, respectively). Median PFS was worse at 8.1 mos in BT vs 11.5 mos in NBT (p = .03). Among BT subgroups, PFS was the longest with IMiD combos with median PFS not reached (NR), comparable to NBT, and was significantly longer than all other BT subgroups (p = 0.01). The median OS was 13.8 mos with BT and NR in NBT (p = .002). In BT subgroup analysis, alkylators had a shorter OS, although, this was not significant (p = .06). There was no significant difference in PFS and OS in relationship to response to BT (p = .6 and p = .9, respectively). Conclusions: Pts without BT had longer PFS and OS post ide-cel, likely reflective of less aggressive disease. Those who received BT with steroid/IMiD and Ab combos had similar PFS as NBT. However, BT choice is complicated by disease severity and should be evaluated per patient circumstances. [Table: see text]" @default.
• W4379344520 created "2023-06-05" @default.
• W4379344520 creator A5001877903 @default.
• W4379344520 creator A5004973468 @default.
• W4379344520 creator A5005843572 @default.
• W4379344520 creator A5008366988 @default.
• W4379344520 creator A5017390274 @default.
• W4379344520 creator A5023064593 @default.
• W4379344520 creator A5026905234 @default.
• W4379344520 creator A5039067043 @default.
• W4379344520 creator A5039680248 @default.
• W4379344520 creator A5042487436 @default.
• W4379344520 creator A5047518602 @default.
• W4379344520 creator A5047819225 @default.
• W4379344520 creator A5053731124 @default.
• W4379344520 creator A5054360080 @default.
• W4379344520 creator A5060313982 @default.
• W4379344520 creator A5062342454 @default.
• W4379344520 creator A5071438752 @default.
• W4379344520 creator A5080882830 @default.
• W4379344520 creator A5082532520 @default.
• W4379344520 creator A5090694142 @default.
• W4379344520 date "2023-06-01" @default.
• W4379344520 modified "2023-09-27" @default.
• W4379344520 title "Impact of bridging therapy (BT) on outcome of relapsed refractory multiple myeloma (RRMM) with Ide-cel CAR T-cell therapy: Real-world experience from the US myeloma CAR T consortium." @default.
• W4379344520 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.8013" @default.
• W4379344520 hasPublicationYear "2023" @default.
• W4379344520 type Work @default.
• W4379344520 citedByCount "0" @default.
• W4379344520 crossrefType "journal-article" @default.
• W4379344520 hasAuthorship W4379344520A5001877903 @default.
• W4379344520 hasAuthorship W4379344520A5004973468 @default.
• W4379344520 hasAuthorship W4379344520A5005843572 @default.
• W4379344520 hasAuthorship W4379344520A5008366988 @default.
• W4379344520 hasAuthorship W4379344520A5017390274 @default.
• W4379344520 hasAuthorship W4379344520A5023064593 @default.
• W4379344520 hasAuthorship W4379344520A5026905234 @default.
• W4379344520 hasAuthorship W4379344520A5039067043 @default.
• W4379344520 hasAuthorship W4379344520A5039680248 @default.
• W4379344520 hasAuthorship W4379344520A5042487436 @default.
• W4379344520 hasAuthorship W4379344520A5047518602 @default.
• W4379344520 hasAuthorship W4379344520A5047819225 @default.
• W4379344520 hasAuthorship W4379344520A5053731124 @default.
• W4379344520 hasAuthorship W4379344520A5054360080 @default.
• W4379344520 hasAuthorship W4379344520A5060313982 @default.
• W4379344520 hasAuthorship W4379344520A5062342454 @default.
• W4379344520 hasAuthorship W4379344520A5071438752 @default.
• W4379344520 hasAuthorship W4379344520A5080882830 @default.
• W4379344520 hasAuthorship W4379344520A5082532520 @default.
• W4379344520 hasAuthorship W4379344520A5090694142 @default.
• W4379344520 hasConcept C10205521 @default.
• W4379344520 hasConcept C120665830 @default.
• W4379344520 hasConcept C121332964 @default.
• W4379344520 hasConcept C126322002 @default.
• W4379344520 hasConcept C141071460 @default.
• W4379344520 hasConcept C142424586 @default.
• W4379344520 hasConcept C2776364478 @default.
• W4379344520 hasConcept C2777371436 @default.
• W4379344520 hasConcept C28328180 @default.
• W4379344520 hasConcept C54355233 @default.
• W4379344520 hasConcept C61511704 @default.
• W4379344520 hasConcept C71924100 @default.
• W4379344520 hasConcept C86803240 @default.
• W4379344520 hasConcept C87355193 @default.
• W4379344520 hasConcept C90924648 @default.
• W4379344520 hasConceptScore W4379344520C10205521 @default.
• W4379344520 hasConceptScore W4379344520C120665830 @default.
• W4379344520 hasConceptScore W4379344520C121332964 @default.
• W4379344520 hasConceptScore W4379344520C126322002 @default.
• W4379344520 hasConceptScore W4379344520C141071460 @default.
• W4379344520 hasConceptScore W4379344520C142424586 @default.
• W4379344520 hasConceptScore W4379344520C2776364478 @default.
• W4379344520 hasConceptScore W4379344520C2777371436 @default.
• W4379344520 hasConceptScore W4379344520C28328180 @default.
• W4379344520 hasConceptScore W4379344520C54355233 @default.
• W4379344520 hasConceptScore W4379344520C61511704 @default.
• W4379344520 hasConceptScore W4379344520C71924100 @default.
• W4379344520 hasConceptScore W4379344520C86803240 @default.
• W4379344520 hasConceptScore W4379344520C87355193 @default.
• W4379344520 hasConceptScore W4379344520C90924648 @default.
• W4379344520 hasIssue "16_suppl" @default.
• W4379344520 hasLocation W43793445201 @default.
• W4379344520 hasOpenAccess W4379344520 @default.
• W4379344520 hasPrimaryLocation W43793445201 @default.
• W4379344520 hasRelatedWork W2002120878 @default.
• W4379344520 hasRelatedWork W2003938723 @default.
• W4379344520 hasRelatedWork W2047967234 @default.
• W4379344520 hasRelatedWork W2118496982 @default.
• W4379344520 hasRelatedWork W2351796763 @default.
• W4379344520 hasRelatedWork W2355902447 @default.
• W4379344520 hasRelatedWork W2435227317 @default.
• W4379344520 hasRelatedWork W2439875401 @default.
• W4379344520 hasRelatedWork W2528057197 @default.
• W4379344520 hasRelatedWork W2525756941 @default.
• W4379344520 hasVolume "41" @default.
• W4379344520 isParatext "false" @default.
• W4379344520 isRetracted "false" @default.
• W4379344520 workType "article" @default.